Intervention[reference] | Duration of intervention | Comparator | Outcomes | Relative risk (95% CI) | NNT/NNH (95% CI) |
---|---|---|---|---|---|
95% CI, 95% confidence interval, AEs, adverse events. | |||||
*Only point estimates of the NNHs were shown owing to the insignificant values of the RR (as shown in the 95% CI). | |||||
NNT | |||||
Cyclofenil [24] | 6 months | Placebo | Ulcers improvement | 2.0 (0.56 to 7.12) | 8.3* |
Iloprost [25] | 38 days | Placebo | Global improvement | 1.61 (0.96 to 2.71) | 4.2* |
Iloprost [25] | 10 weeks | Placebo | Digital ulcers healed | 8.12 (0.57 to 115.07) | 1.2* |
Cisaprost [25] | 45 days | Placebo | Global improvement | 1.14 (0.54 to 2.4) | 16.1* |
Ketanserin [26] | 3–6 months | Placebo | Global improvement | 3.07 (0.54 to 17.46) | 2.3* |
Prazosin [27] | 6 weeks | Placebo | Global improvement | 3.0 (0.15 to 59.89) | 5.0* |
NNH | |||||
Cyclofenil [24] | 6 months | Placebo | Withdrawals due to AEs | 1.5 (0.46 to 4.89) | 18.9* |
Iloprost [25] | 38 days–11 weeks | Placebo | With AEs | 2.05 (1.41 to 2.98) | 2.1 (1.7 to 2.8) |
Cisaprost [25] | 45 days | Placebo | With AEs | 1.2 (0.75 to 1.93) | 8.0* |
Ketanserin [26] | 3 months | Placebo | Withdrawals due to AEs | 2.71 (0.4 to 18.33) | 2.2 (1.2 to 8.6) |
Prazosin [27] | 4 weeks | Placebo | Withdrawals due to AEs | 4.17 (0.23 to 77.11) | 5.5* |